ArticleNeurochemical research2025
Neuroprotective Effects of Ammi visnaga Fruit Hydroalcoholic Extract in a PTZ-Induced Seizure Mouse Model: Emphasis on Neuroinflammatory Pathways.
Article in Neurochemical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epilepsy affects over 65 million individuals worldwide, with approximately 30% of patients resistant to conventional antiepileptic drugs (AEDs). Neuroinflammation and oxidative stress are recognized contributors to epileptogenesis and seizure severity. Ammi visnaga (toothpick plant), traditionally used for its anti-inflammatory and antioxidant properties, remains understudied in the context of seizure-related neuroinflammation. This study aimed to investigate the neuroprotective, anticonvulsant, anti-inflammatory, and antioxidant properties of Ammi visnaga fruit hydroalcoholic extract in a pentylenetetrazole (PTZ)-induced seizure model in mice, with a particular focus on hippocampal oxidative stress and cytokine modulation. Forty adult male NMRI mice were randomized into Six groups including: both healthy negative control and PTZ + saline control, PTZ-only, phenobarbital-treated, and Ammi visnaga-treated (25, 50, and 100 mg/kg). Seizure latency, hippocampal expression of IL-6 and TNF-α (via qPCR) and oxidative stress biomarkers (MDA, nitrite, TAC) were assessed. Seizure latency significantly increased with Ammi visnaga treatment in a dose-dependent manner (P < 0.0001), with the 100 mg/kg group showing a robust delay compared to the PTZ group. Cytokine mRNA expression (IL-6 and TNF-α, measured by qPCR) were markedly downregulated in all extract-treated groups, reaching levels comparable to healthy controls (P < 0.001). Oxidative stress markers showed clear modulation; MDA and nitrite levels were significantly reduced in the hippocampus and serum at 100 mg/kg (P < 0.01 and P < 0.05, respectively). Total antioxidant capacity (TAC) was substantially enhanced in both serum and hippocampal tissue, particularly in the 50 and 100 mg/kg groups (P < 0.0001). In contrast, phenobarbital elevated seizure threshold but had minimal impact on oxidative stress biomarkers. Ammi visnaga fruit hydroalcoholic extract demonstrated potent, dose-dependent neuroprotective effects in a PTZ-induced seizure model through dual anti-inflammatory and antioxidative mechanisms. Its ability to suppress IL-6 and TNF-α expression and restore redox balance positions it as a promising adjunctive therapeutic candidate for epilepsy management, especially in drug-resistant cases driven by neuroinflammation and oxidative stress.
Indexed as
Identifiers
41182468What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.